Nonoperating Income (Expense) of Anebulo Pharmaceuticals, Inc. from 30 Jun 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Anebulo Pharmaceuticals, Inc. quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 30 Jun 2020 to 31 Dec 2025.
  • Anebulo Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending 31 Dec 2025 was $620,513, a 396% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending 31 Dec 2025 was $1,124,628, a 233% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2025 was $738,718, a 590% increase from 2024.
  • Anebulo Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2024 was $107,052, a 109% increase from 2023.
  • Anebulo Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $51,261, a 823% increase from 2022.
Source SEC data
View on sec.gov
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

Anebulo Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,124,628 $620,513 +$495,392 +396% 01 Oct 2025 31 Dec 2025 10-Q 12 Feb 2026 2026 Q2
Q3 2025 $629,236 $101,906 -$109,482 -52% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q1
Q2 2025 $738,718 $186,056 +$195,658 01 Apr 2025 30 Jun 2025 10-K 29 Sep 2025 2025 FY
Q1 2025 $543,060 $216,153 +$205,444 +1918% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q3
Q4 2024 $337,616 $125,121 +$82,031 +190% 01 Oct 2024 31 Dec 2024 10-Q 12 Feb 2026 2026 Q2
Q3 2024 $255,585 $211,388 +$148,533 +236% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q1
Q2 2024 $107,052 $9,602 -$8,835 -1152% 01 Apr 2024 30 Jun 2024 10-K 29 Sep 2025 2025 FY
Q1 2024 $115,887 $10,709 -$55,361 -84% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q3
Q4 2023 $171,248 $43,090 +$56,920 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025 2025 Q2
Q3 2023 $114,328 $62,855 +$63,067 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2025 Q1
Q2 2023 $51,261 $767 01 Apr 2023 30 Jun 2023 10-K 25 Sep 2024 2024 FY
Q1 2023 $66,070 +$62,917 +1995% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q3
Q4 2022 $13,830 01 Oct 2022 31 Dec 2022 10-Q 13 Feb 2024 2024 Q2
Q3 2022 $212 -$1,741 -114% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q1
Q1 2022 $3,153 +$6,854 01 Jan 2022 31 Mar 2022 10-Q 11 May 2022 2022 Q3
Q3 2021 $1,529 +$5,562 01 Jul 2021 30 Sep 2021 10-Q 12 Nov 2021 2021 Q1
Q1 2021 $3,701 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q3
Q3 2020 $4,033 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q1
Q2 2020 $1,286 23 Apr 2020 30 Jun 2020 10-K 22 Sep 2021 2021 FY

Anebulo Pharmaceuticals, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $738,718 +$631,666 +590% 01 Jul 2024 30 Jun 2025 10-K 29 Sep 2025 2025 FY
2024 $107,052 +$55,791 +109% 01 Jul 2023 30 Jun 2024 10-K 29 Sep 2025 2025 FY
2023 $51,261 +$45,706 +823% 01 Jul 2022 30 Jun 2023 10-K 25 Sep 2024 2024 FY
2022 $5,555 +$26,644,356 01 Jul 2021 30 Jun 2022 10-K 22 Sep 2023 2023 FY
2021 $26,638,801* 01 Jul 2020 30 Jun 2021 10-K 09 Sep 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.